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Editorial
Randomized clinical trial is often considered as the Gold
Standard method for comparing treatment effects. In prac-
tice, taking into consideration their main objectives, the
majority of clinical trials are aimed to establish the supe-
riority of an intervention regarding to an active control or
placebo [1]. Within the methodological core of these so
called superiority trials, the assessment of the statistical sig-
nification of the differences between or among interven-
tions, and their clinical relevance, are both of main
importance. Appropriate statistical tests to assess this
superiority should be performed, with the null hypothesis
being: the difference between treatments is equal to 0 (H0   
= 0), and the alternative hypothesis: treatments are different
-or, the difference between treatments is not equal to 0 (H1   
 0)(if two sided)-. The rejection of the null hypothesis is in
the foundation of the methodological assessment of supe-
riority [2]. The number of patients required to confront
the hypotheses is inversely related to the expected
between-treatment differences. The smallest the expected
difference between two interventions, the highest the
number of patients to be included into the trial. But, how
to interpret a non-significant result obtained from a clini-
cal study designed as a superiority trial? Does this mean
that the interventions under study should be considered
as equivalent?. Clearly, the answer is negative. From the
methodological standpoint, the expression: we have no evi-
dence of difference between treatments, should not be con-
sidered as equivalent to: we have evidence of no difference
between interventions [3].
Very often, the aim of a clinical trial is to show that a cer-
tain intervention is equivalent to or non inferior than
another one. In this case, as stated before, a non-signifi-
cant superiority testing should not be interpreted as a
proof of no difference between treatments. Under an
equivalence hypothesis, where the between treatments
difference is assumed to be equal to 0, the calculation of a
sample size following the rules established for superiority
trials is impossible or in the best case (by employing an
estimated difference close to 0) would result in an unreal-
istic extremely large number [1]. Instead, equivalence and
non-inferiority trials should be conceived, planned and
applied to these purposes. In general, neither equivalence
nor non-inferiority should be definitively concluded from
superiority trials exhibiting non-significant results.
Improvements into the galenics of a formulation or a
modification in a drug delivery system should not affect
the pharmacokinetic (PK) profile of the drug. That is also
the case for the comparison between the PK parameters of
a generic preparation versus an original product. This is
the rationale for the so called bioequivalence trials, the most
frequent type of equivalence study. Being μS the mean
value for an specific PK indicator in the standard or the
original product, and μT the mean for the same parameter
of the new product under testing, the null hypothesis in a
bioequivalence trial would be: H0 ≡ μS-μT ≤ -Δ or μS-μT>Δ,
(where Δ is the magnitude of a prespecified difference
between the standard (S) and the new product T. Typi-
cally, the main PK indicators under study are: the peak
concentration of the drugs on trial (Cmax), their areas-
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under-the-curve of concentrations in relation to time
(AUC) and the time-to-peak (Tmax) [4].
The purpose of a "non-inferiority trial" is to show that a
new intervention is no worse than the standard reference
therapy. Here, the assumption is that the difference in
effect is no less than a prespecified Δ. It should be
designed as a one-sided trial. The null hypothesis is: H0 ≡
πS-πT ≥ M, being πS and πT the outcomes rate for a qualita-
tive dependent variable (e.g. death, infarctions, stroke),
and M a maximum allowable limit of difference, or, H0 ≡
μS-μT ≥ M in case of a quantitative outcome (where μ are
means).
Non-inferiority trials are carried out when: 1) a placebo-
controlled trial is not ethically feasible; 2) the treatment
under test is not expected to be better that the standard or
reference intervention in terms of efficacy, but is suppos-
edly better regarding to other secondary endpoints, safety,
costs, compliance or convenience [2].
In non-inferiority trials, the choice of the maximum
allowable margin is crucial. The rationale to determine
these limits require careful consideration and should be
appropriately described into the specific section of the
protocol. ASSENT 2 trial is an early example of non-infe-
riority trial within the scope of thrombolytic therapy
[5,6]. Alternative hypothesis in this study was that the 30
days mortality is not inferior for a single bolus of tec-
neplase when compared with an accelerate infusion of
alteplase. The path to determine the allowable margin
involved several steps. It was finally accepted that consid-
ering an event rate cut off of 7.2% in patients treated with
alteplase, the non-inferiority area could be defined as fol-
lows: if πS (alteplase events rate) were >7.2%, then πS-πT
(difference in events between alteplase and tecneplase)
<1%; in case of a πS < 7.2%, a ratio πS/πT < 1.14 would be
considered as within the non-inferiority region. Results of
this trial showed that the events rate for the alteplase
treated group was 6.18%; in the tecneplase treated
patients was 6.16%. Events rate in the alteplase group was
below 7.2; as the ratio πS/πT was 0.99 (with a 90% confi-
dence interval of 0.90 to 1.10) always below 1.14 (even
considering the upper 90% confidence interval limit), the
non-inferiority hypothesis was considered as proven.
TARGET (Do Tirofiban and ReoPro Give Similar Efficacy
Outcomes Trial) is another good example of non-inferior-
ity trial, comparing two glycoprotein IIb/IIIa receptor
blockers [7]; nevertheless, in this case, tirofiban failed to
demonstrate non-inferiority to abciximab (the ischemic
event rate was higher in the tirofiban group).
Non-inferiority trials offer some issues to the methodo-
logical debate: selection of the appropriate margin could
be sometimes considered as arbitrary (it is dependant on
the indication, the clinical judgment and the regulatory
guidance), and in many occasions would require a clear
estimation/prediction of the effect of the control therapy
(and this is not always available). While in superiority tri-
als intention-to-treat (ITT) based analysis is always recom-
mendable, it is unclear that this approach could provide
any benefits in non-inferiority trials and "per procolol"
analyses are preferred by some authors. In the ITT
approach, all patients we intended to treat will be
included into the analysis, whether they completed the
trial following the protocol or not. The purpose is to min-
imize the potential impact of withdrawals and non-com-
pliance on the interpretation of the results. Conversely, in
a "as per protocol" breakdown, patients who were non-
compliant, or unable to complete the assigned treatment
or have missing data are excluded from the analysis. In a
pragmatic approach, most of the specialists recommend
to apply both ITT and "per protocol" analyses, assuring
that the results of these two analysis are not conflictive.
Nevertheless, in the field of non-inferiority trials, this
issue is still a matter of methodological controversy [2,8].
In spite of the limitations in the doctrine that supports the
classification of the clinical experiments as "superiority",
"equivalence" and "non-inferiority" trials, this methodo-
logical approach allowed for a improved production and
understanding of the medical evidence when compared
with the traditional view. Further epistemological refine-
ments of this theory are granted.
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